Monoclonal antibody ADCC cHAb18 - Pacific Meinuoke Biopharmaceutical
Alternative Names: HAb18G/CD147-targeting monoclonal antibodyLatest Information Update: 28 Dec 2018
Price :
$50 *
At a glance
- Originator Pacific Meinuoke Biopharmaceutical
- Developer Fourth Military Medical University; Pacific Meinuoke Biopharmaceutical
- Class Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Membrane glycoprotein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Lung cancer
Most Recent Events
- 28 Dec 2018 No recent reports of development identified for clinical-Phase-Unknown development in Lung-cancer in China (Parenteral)
- 27 Nov 2015 Clinical trials in Lung cancer in China (Parenteral)